Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
The DOI matches its Crossref record; 121 of the 123 references it cites were found in a registry or an index.
Abstract
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently become a major concern for a broad spectrum of health care providers. Endocrinologists and those caring for patients with type 2 diabetes mellitus (T2DM) are at center stage, as T2DM appears to worsen the course of NAFLD and the liver disease makes diabetes management more challenging. However, the nature of this relationship remains incompletely understood. Although the increasing prevalence of NAFLD is frequently attributed to the epidemic of obesity and is often oversimplified as the "hepatic manifestation of the metabolic syndrome," it is a much more complex disease process that may also be observed in nonobese individuals and in patients without clinical manifestations of the metabolic syndrome. It carries both metabolic and liver-specific complications that make its approach unique among medical conditions. Diabetes appears to promote the development of nonalcoholic steatohepatitis (NASH), the more severe form of the disease, and increases the risk of cirrhosis and hepatocellular carcinoma. Patients and physicians face many uncertainties, including fragmented information on the natural history of the disease, challenges in the diagnosis of NASH, and few pharmacological agents with proven efficacy. However, recent advances in diagnosis and treatment, combined with the risk of serious consequences from inaction, call for health care providers to be more proactive in the managem…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NAFLD, and in particular NASH, is also associated with an increased risk of cardiovascular complications; therefore, people with NAFLD should have their cardiovascular risk factors assessed and managed to minimize this risk (303).”
In the citing paper
“Rat studies have shown that removal of visceral adipose tissue increases insulin sensitivity while delaying T2D (75), and prevents metabolic syndrome and NAFLD (76).”
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Research works printed but not linked: 1
- Sanyal, 2016, Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: results from the Year 1 primary analysis of the Phase 2b CENTAUR study (Abstract), Hepatology, 64, 1118A
Cited by
Items 101–200 of 341
Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
Kechagias, S., Ekstedt, M., Simonsson, C., & Nasr, P. (2022) · Hormones · doi:10.1007/s42000-022-00377-8 · Cited by 39
Lyu, J., Imachi, H., Fukunaga, K., Sato, S., Kobayashi, T., Dong, T., Saheki, T., Matsumoto, M., Iwama, H., Zhang, H., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.12.015 · Cited by 36
Sigala, D. M., Hieronimus, B., Medici, V., Lee, V., Nuñez, M. V., Bremer, A. A., Cox, C. L., Price, C. A., Benyam, Y., Chaudhari, A. J., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab508 · Cited by 43
Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
Snyder, H. S., Sakaan, S. A., March, K. L., Siddique, O., Cholankeril, R. T., Cummings, C. D., Gadiparthi, C., Satapathy, S. K., Ahmed, A., & Cholankeril, G. T. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00050 · Cited by 42
Mansour, A., Mohajeri‐Tehrani, M. R., Samadi, M., Gerami, H., Qorbani, M., Bellissimo, N., Poustchi, H., & Hekmatdoost, A. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01374-x · Cited by 35
Browning, M. G., Khoraki, J., DeAntonio, J. H., Mazzini, G. S., Mangino, M. J., Siddiqui, M. S., Wolfe, L. G., & Campos, G. M. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.309 · Cited by 36
NAFLD in type 2 diabetes mellitus: Still many challenging questions
Cernea, S., & Raz, I. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3386 · Cited by 38
Fujihara, K., Matsubayashi, Y., Yamamoto, M., OSAWA, T., Ishizawa, M., Kaneko, M., Matsunaga, S., Kato, K., Seida, H., YAMANAKA, N., et al. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.08.002 · Cited by 32
Quesada, I., Cejas, J. B., García, R. D., Cannizzo, B., Redondo, A. L., & Castro, C. (2018) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12322 · Cited by 32
Wei, D., Wu, S., Liu, J., Zhang, X., Guan, X., Gao, L., & Xu, Z. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0259 · Cited by 32
Lin, C., Adhikary, P., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.008 · Cited by 35
Serum Bile Acid Profiles Improve Clinical Prediction of Nonalcoholic Fatty Liver in T2DM patients
Wu, T., Yang, M. S., Xu, H., Wang, L., Wei, H., & Ji, G. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00104 · Cited by 32
Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease
Lyu, J., Lin, Q., Fang, Z., Xu, Z., & Liu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032557 · Cited by 36
Ciardullo, S., Sala, I., & Perseghin, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108358 · Cited by 34
Bilson, J., Scorletti, E., Bindels, L. B., Afolabi, P. R., Targher, G., Calder, P. C., Sethi, J. K., & Byrne, C. D. (2021) · Nutrition and Diabetes · doi:10.1038/s41387-021-00170-3 · Cited by 33
Lee, D. S., An, T. H., Kim, H.-M., Jung, E., Kim, G., Oh, S. Y., Kim, J. S., Chun, H. J., Jung, J., Lee, E., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05878-8 · Cited by 32
Zarean, E., Goujani, R., Rahimian, G., & Ahamdi, A. (2019) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2019.87635 · Cited by 30
Yang, B. J., Han, X., Liu, D., Tan, Z., & Deng, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1072376 · Cited by 32
Sakayanathan, P., Loganathan, C., Iruthayaraj, A., Kumaradhas, P., & Palvannan, T. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117367 · Cited by 34
Cossiga, V., Lembo, V., Nigro, C., Mirra, P., Miele, C., D’Argenio, V., Leone, A., Mazzone, G., Veneruso, I., Guido, M., et al. (2021) · Nutrients · doi:10.3390/nu13041281 · Cited by 30
Kurinami, N., Sugiyama, S., Morita, A., Yoshida, A., Hieshima, K., MIYAMOTO, F., Kajiwara, K., Jinnouch, K., Jinnouchi, T., & Jinnouchi, H. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.009 · Cited by 29
Key genes and co‐expression network analysis in the livers of type 2 diabetes patients
Li, L., Pan, Z., & Yang, X. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12998 · Cited by 29
Dietary Niacin Intake Predicts the Decrease of Liver Fat Content During a Lifestyle Intervention
Linder, K., Willmann, C., Kantartzis, K., Machann, J., Schick, F., Graf, M., Kümmerle, S., Häring, H., Fritsche, A., Stefan, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38002-7 · Cited by 32
Ultrasound imaging in nonalcoholic liver disease: current applications and future developments
Yang, K., Liao, Y., Tsui, P., & Yeh, C. (2019) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2019.03.14 · Cited by 26
Raschi, E., Mazzotti, A., Poluzzi, E., Ponti, F. D., & Marchesini, G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1531126 · Cited by 29
Magic and mystery of microRNA‐32
Zeng, Z., Zhu, Q., Zhao, Z., Zu, X., & Liu, J. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16861 · Cited by 27
Lu, Y., Hu, L., Song, J., Wan, J., Chen, H., & Yin, J. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00899-z · Cited by 27
NAFLD and type 2 diabetes: A practical guide for the joint management
Genua, I., Iruzubieta, P., Rodríguez-Duque, J. C., Pérez, A., & Crespo, J. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.12.002 · Cited by 25
The nature and characteristics of hypertriglyceridemia in a large cohort with type 2 diabetes
Echegoyen, F. F. B., Szeto, A., Mendez, A. J., Garg, R., & Goldberg, R. B. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108387 · Cited by 25
Emerging Role of Protein O-GlcNAcylation in Liver Metabolism: Implications for Diabetes and NAFLD
Xie, Z., Xie, T., Liu, J., Zhang, Q., & Xiao, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032142 · Cited by 25
Hígado graso no alcohólico: una pandemia poco conocida
Augustín, S., Graupera, I., & Caballería, J. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.06.026 · Cited by 25
Yip, T. C., Wong, V. W., Chan, H. L., Tse, Y., Hui, V. W., Liang, L. Y., Lee, H. W., Lui, G. C.-Y., Kong, A. P. S., & Wong, G. L. (2020) · Journal of Viral Hepatitis · doi:10.1111/jvh.13307 · Cited by 25
Multidisciplinary Approach to Management and Care of Patients with Type 2 Diabetes Mellitus
Bain, S., Cummings, M. H., & McKay, G. A. (2019) · EMJ Diabetes · doi:10.33590/emjdiabet/10314374 · Cited by 22
Della Pepa, G., Vetrani, C., Brancato, V., Vitale, M., Monti, S., Annuzzi, G., Lombardi, G., Izzo, A., Tommasone, M., Cipriano, P., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001342 · Cited by 22
Julián, M. T., Pera, G., Soldevila, B., Caballería, L., Julve, J., Puig-Jové, C., Morillas, R. M., Torán‐Monserrat, P., Expósito, C., Puig‐Domingo, M., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1240 · Cited by 23
Self-citationThe Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma
Sherif, Z. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85780 · Cited by 27
Hendawy, O. M., Gomaa, H. A. M., Hussein, S., Alzarea, S. I., Qasim, S., Rahman, F. E.-Z. S. A., Ali, A. T., & Ahmed, S. R. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.09.014 · Cited by 23
Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides‐Brears, H., Wilding, J. P. H., & Cuthbertson, D. J. (2020) · Diabetic Medicine · doi:10.1111/dme.14356 · Cited by 21
Klisic, A. N., Kavarić, N., & Ninić, A. (2019) · Journal of Medical Biochemistry · doi:10.2478/jomb-2019-0001 · Cited by 21
Perdomo, C. M., García-Fernández, N., & Escalada, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092040 · Cited by 23
Anti-diabetic drugs and NASH: from current options to promising perspectives
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951701 · Cited by 22
Li, Y., Li, Y., Chen, N., Feng, L., Gao, J., Zeng, N., He, Z., & Gong, Q. (2022) · Antioxidants · doi:10.3390/antiox11091705 · Cited by 26
Hnilicová, P., Kantorová, E., Šutovský, S., Grofik, M., Zeleňák, K., Kurča, E., Žilka, N., Parvanovova, P., & Kolísek, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043325 · Cited by 23
Yu, C., Wang, L., Xue, H., Lin, H., Li, Y., & Chan, S. O. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.08.007 · Cited by 22
Sebastiani, G., Patel, K., Ratziu, V., Feld, J. J., Neuschwander‐Tetri, B. A., Pinzani, M., Petta, S., Berzigotti, A., Metrakos, P. P., Shoukry, N. H., et al. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2021-0030 · Cited by 21
Khaliq, A., Badshah, H., Shah, Y., Rehman, I. U., Khan, K. U., Ming, L. C., & Cheng, M. H. (2024) · Medicine · doi:10.1097/md.0000000000040356 · Cited by 26
Zhang, Y., Li, J., Liu, H., Li, L., Zhang, J., Wang, Y., & Zhang, Z. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01050-2 · Cited by 23
One-hour post-load glucose is associated with severity of hepatic fibrosis risk
Jagannathan, R., Fiorentino, T. V., Marini, M. A., Sesti, G., & Bergman, M. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109977 · Cited by 21
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes
Hoyt, J. A., Cozzi, E., D’Alessio, D. A., Thompson, C. C., & Aroda, V. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15533 · Cited by 21
ALVARES, D. C. L., HOFFMAN, S. S., Stankovic, B., & Adeli, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.12.010 · Cited by 22
Erickson, M. L., Haus, J. M., Malin, S. K., Flask, C. A., McCullough, A. J., & Kirwan, J. P. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.06.012 · Cited by 19
Augustín, S., Ahmed, A., Alkhouri, N., Canbay, A. E., Corless, L., Nakajima, A., Okanoue, T., Petta, S., Ratziu, V., Tsochatzis, E. A., et al. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-775 · Cited by 20
Du, J., Chai, S., Zhao, X., Sun, J., Zhang, X., & Huo, L. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313503 · Cited by 20
Nonalcoholic Fatty Liver Disease and Mortality
Stefan, N. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.02.016 · Cited by 18
The interaction of Schistosoma mansoni infection with diabetes mellitus and obesity in mice
Amer, A. S., Othman, A. A., Dawood, L. M., El-Nouby, K. A., Gobert, G. N., & Rayia, D. M. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-36112-5 · Cited by 18
Dobbie, L. J., Kassab, M., Davison, A., Grace, P., Cuthbertson, D. J., & Hydes, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245755 · Cited by 18
Soltanieh, S., Salavatizadeh, M., Poustchi, H., Yari, Z., Mansour, A., Khamseh, M. E., Malek, M., Alaei-Shahmiri, F., & Hekmatdoost, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13983 · Cited by 22
Bril, F., & Elbert, A. E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156066 · Cited by 17
Self-citationNon‑alcoholic fatty liver disease: A major challenge in type�2 diabetes mellitus (Review)
Bică, C., Sandu, C., Suceveanu, A., Sarbu, E., Stoica, R. A., Gherghiceanu, F., Bohîlțea, R. E., Ștefan, S., & Stoian, A. P. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8882 · Cited by 22
Traditional Chinese Medicine and Intestinal Microbiota
Liang, Y., Lin, C., Huang, S., & Xu, Y. (2019) · Holistic Nursing Practice · doi:10.1097/hnp.0000000000000311 · Cited by 18
Wang, M., Zhao, Y., He, Y., Zhang, L., Liu, J., Zheng, S., & Bai, Y. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.018 · Cited by 18
Yeh, M., Huang, J., Dai, C., Huang, C., Yu, M., & Chuang, W. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2388790 · Cited by 16
NASH‐related cirrhosis: An occult liver disease burden
Arrese, M. A., & Feldstein, A. E. (2017) · Hepatology Communications · doi:10.1002/hep4.1033 · Cited by 16
High glucose promotes hepatic fibrosis via miR‑32/MTA3‑mediated epithelial‑to‑mesenchymal transition
Li, Q., Li, Z., Lin, Y., Che, H., Hu, Y., Kang, X., Zhang, Y., Wang, L., & Zhang, Y. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9986 · Cited by 18
Wang, X., Li, H., Ji, L., Cang, J., & Zhao, H. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1045141 · Cited by 18
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 17
Self-citationPerdomo, C. M., Ezponda, A., Núñez-Córdoba, J. M., Herrero, J. I., Bastarrika, G., Frühbeck, G., & Escalada, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-10487-3 · Cited by 15
Park, J., Kim, G., Kim, B., Han, K., Kwon, S. Y., Park, S., Lee, Y., Jin, S., & Kim, J. H. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110191 · Cited by 17
Ssentongo, P., Ssentongo, A. E., Dykes, T. M., Pauli, E. M., & Soybel, D. I. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.07.655 · Cited by 16
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus
Cusi, K. J. (2017) · Gut · doi:10.1136/gutjnl-2017-313958 · Cited by 15
Self-citationFalalyeyeva, T. M., Komisarenko, I., Yanchyshyn, A., Kovalchuk, O. I., Lozko, Y., Tsyryuk, O., Fagoonee, S., & Kobyliak, N. M. (2021) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.21.02766-x · Cited by 15
Beiriger, J., Chauhan, K., Khan, A., Shahzad, T., Parra, N. S., Zhang, P. G. Y., Chen, S., Nguyen, T. A., Yan, B. M., Bruckbauer, J., et al. (2023) · Livers · doi:10.3390/livers3040042 · Cited by 17
Non-alcoholic fatty liver disease: A poorly known pandemic
Augustín, S., Graupera, I., & Caballería, J. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.11.009 · Cited by 15
Chhabra, S., Singh, S., Singh, A., Mehta, V., Kaur, A., Bansal, N., & Sood, A. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.07.001 · Cited by 18
Salmi, A., di Filippo, L., Ferrari, C., Frara, S., & Giustina, A. (2022) · Endocrine · doi:10.1007/s12020-022-03157-x · Cited by 15
Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
Ni, K., & Meng, L. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102381 · Cited by 16
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis
Bril, F., & Cusi, K. J. (2017) · Annals of Internal Medicine · doi:10.7326/l16-0629 · Cited by 13
Self-citationLin, J., Li, H., & Wan, Q. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s375300 · Cited by 14
Cazac, G.-D., Lăcătușu, C.-M., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2022) · Biomedicines · doi:10.3390/biomedicines10102375 · Cited by 15
Spradley, F. T., Smith, J. A., Alexander, B. T., & Anderson, C. D. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00394.2017 · Cited by 14
Lack of awareness of liver organ damage in patients with type 2 diabetes
Ciardullo, S., Monti, T., & Perseghin, G. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01677-y · Cited by 13
Targher, G. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.10.21 · Cited by 16
Shen, T., Aby, E. S., Vock, D. M., & Farley, J. F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15853 · Cited by 13
Chen, S., Suo, J., Wang, Y., Tang, C., Ma, B., Li, J., Hou, Y., Yan, B., Shen, T., Zhang, Q., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107812 · Cited by 14
Han, J.-J., Li, J., & Huang, D.-H. (2024) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-024-00675-9 · Cited by 13
Bril, F., Bolla, P., Huynh, K., & Bobba, S. S. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf110 · Cited by 13
Self-citationAlexopoulos, A., Duffy, R., Kobe, E. A., German, J., Moylan, C. A., Soliman, D., Jeffreys, A. S., Coffman, C. J., & Crowley, M. J. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab155 · Cited by 13
Mansour, A., Motamed, S., Hekmatdoost, A., Karimi, S., Mohajeri‐Tehrani, M. R., Abdollahi, M. R., Jelodar, R., & Sajjadi‐Jazi, S. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-30945-w · Cited by 15
Cossiga, V., Lembo, V., Guarino, M., Tuccillo, C., Morando, F., Pontillo, G., Fiorentino, A., Caporaso, N., & Morisco, F. (2019) · Nutrients · doi:10.3390/nu11123070 · Cited by 13
Wang, S., Cai, B., Han, X., Gao, Y., Zhang, X., Wang, R., Zhang, Y., & Chen, Q. (2020) · Medicine · doi:10.1097/md.0000000000020148 · Cited by 12
Naeem, M. T., Bülow, R., Schipf, S., Werner, N. L., Dörr, M., Lerch, M. M., Kühn, J., Rathmann, W., Nauck, M. A., Markus, M. R. P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92681-3 · Cited by 13
Dai, W., Zhang, Z., & Zhao, S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.680664 · Cited by 15
García‐Escobar, E., Valdés, S., Soriguer, F., Vendrell, J. J., Urrutia-Etxebarria, I. M., Maldonado‐Araque, C., Ortega, E., Ocón, P., Montanya, E., Menéndez, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95546-x · Cited by 13
Asero, C., Giandalia, A., Cacciola, I., Morace, C., Lorello, G., Caspanello, A. R., Alibrandi, A., Squadrito, G., & Russo, G. T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082858 · Cited by 11
Vornoli, A., Vizzarri, F., Croce, C. M. D., Grande, T., Palazzo, M., Árvay, J., Pucci, L., Gabriele, M., Matteucci, M., Paolini, M., et al. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113261 · Cited by 11
Prevention of type 2 diabetes: what is the right target population?
Williamson, D. A. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1535896 · Cited by 13
Neuronal Lipoprotein Lipase Deficiency Alters Neuronal Function and Hepatic Metabolism
Bruce, K. D., Wang, H., Dobrinskikh, E., Rudenko, I. A., Gao, H., Libby, A. E., Gorkhali, S., Yu, T., Zsombok, A., & Eckel, R. H. (2020) · Metabolites · doi:10.3390/metabo10100385 · Cited by 11
Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Leiva, E. G., & Bril, F. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201209203534 · Cited by 12
Self-citationBeauchamp, G., Barr, M. M., Vergara, A., Ashraf, A. P., & Bril, F. (2021) · International Journal of Pediatrics and Adolescent Medicine · doi:10.1016/j.ijpam.2021.02.007 · Cited by 11
Self-citationТкач, С. М., Pankiv, V. І., & Krushinska, Z. H. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.1.2024.1353 · Cited by 10
Metadata
- Authors
- Bril, F., & Cusi, K.
- Affiliations
- University of Florida Health (US)
- Corresponding author
- Cusi, Kenneth
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-02-13
- Volume
- 40
- Issue
- 3
- Pages
- 419-430
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2589426226
- Cited by
- 341
- References
- 123
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 28 · 2023: 38 · 2022: 41 · 2021: 43 · 2020: 61 · 2019: 41 · 2018: 36 · 2017: 17
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, type 2 diabetes, nonalcoholic steatohepatitis, metabolic syndrome, obesity, liver cirrhosis, hepatocellular carcinoma, NASH diagnosis, NASH treatment, disease natural history
- MeSH terms
- Diabetes Mellitus, Type 2, Carcinoma, Hepatocellular, Humans, Hyperglycemia, Life Style, Liver Neoplasms, Obesity, Risk Factors, Prevalence, Randomized Controlled Trials as Topic, Metabolic Syndrome, Dyslipidemias, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.